The Centers for Medicare & Medicaid Services (CMS) has proposed repealing a payment pathway that allows breakthrough medical devices to receive supplementary reimbursements, according to a policy announcement released this week. The move, which would roll back a 2021 initiative, has sparked debate among industry stakeholders and healthcare analysts.
The pathway was originally introduced to provide temporary Medicare coverage for devices designated as “breakthrough” by the Food and Drug Administration (FDA). These devices are typically innovative technologies that address unmet medical needs. CMS officials argue that the current pathway lacks sufficient safeguards to ensure cost-effectiveness and clinical effectiveness.
“The goal was to accelerate patient access to cutting-edge treatments,” said a CMS spokesperson, who requested anonymity. “However, we must balance innovation with fiscal responsibility and ensure that taxpayer dollars are spent wisely.”
Industry leaders, however, warn that the repeal could stifle innovation. “This decision could discourage investment in breakthrough technologies,” said a representative from the Advanced Medical Technology Association (AdvaMed).
Analysts suggest that the proposed change could have broader implications for the healthcare sector, potentially slowing the adoption of new technologies and impacting manufacturers’ revenue streams. The policy is subject to a public comment period before finalization, with stakeholders on both sides expected to weigh in heavily.